[EVALUATION OF THE CURRENT THERAPEUTIC TRENDS IN HODGKIN'S DISEASE. CRITICAL REVIEW AND CASUISTIC CONTRIBUTION].
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D001388:Aziridines; D016026:Bone Marrow Transplantation; D003078:Colchicine; D003520:Cyclophosphamide; D003609:Dactinomycin; D006689:Hodgkin Disease; D008466:Mechlorethamine; D008558:Melphalan; D009369:Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes; D011882:Radiotherapy, High-Energy; D014265:Triethylenemelamine; D014747:Vinblastine
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D001388:Aziridines; D011868:Radioisotopes; D003609:Dactinomycin; D008466:Mechlorethamine; D014747:Vinblastine; D003520:Cyclophosphamide; C026480:inproquone; D014265:Triethylenemelamine; D008558:Melphalan; D003078:Colchicine
ACTINOMYCIN; ADRENAL CORTEX HORMONES; ANTIBIOTICS; ANTINEOPLASTIC AGENTS; BAYER E39; BONE MARROW TRANSPLANTATION; COLCHICINE; CYCLOPHOSPHAMIDE; HODGKIN'S DISEASE; MECHLORETHAMINE; MELPHALAN; NEOPLASM RADIOTHERAPY; RADIOISOTOPES; RADIOTHERAPY, HIGH ENERGY; TRIETHYLENE MELAMINE; VINBLASTINE